Tecan Revises 2024 Outlook Amid Market Challenges
Tecan reports lower H1 2024 sales, revises full-year outlook due to biopharma sector weakness and market challenges in China.
- Latest
- Trending
Tecan reports lower H1 2024 sales, revises full-year outlook due to biopharma sector weakness and market challenges in China.
Mt. Gox trustee's $2 billion BTC transfer hints at creditor payouts, with BitGo likely managing the process. Arkham tracks developments.
Only 66% of Ethereum holders profit despite a 21% price surge, indicating challenges for the cryptocurrency.
Ethereum price surges over 8%, surpassing Bitcoin with resistance levels at $2,750 and $2,880 in sight.
Federal court halts Missouri's ESG investing rules, citing SEC's regulatory authority over investment firms.
IntoTheBlock data reveals 66% of ETH addresses in profit, with ETH near $2,600, up from prior lows.
A whale investor earns $153M on Ethereum after a 9-year hold, signaling potential market shifts.
Senmiao Technology reports widened net loss of $673.4k, a 57% increase. Revenue declines 46% year-over-year.
Explore if Alphabet stock remains a buy as it faces legal action. Understand the implications for investors.
Digihost Technology's Q2 2024 revenue rose 57%, beating analyst estimates by 14%, despite a widened net loss.
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.